Nicholson Wealth Management Group LLC Purchases New Position in Becton, Dickinson and Company (NYSE:BDX)

Nicholson Wealth Management Group LLC acquired a new position in Becton, Dickinson and Company (NYSE:BDX) during the 3rd quarter, HoldingsChannel.com reports. The fund acquired 2,854 shares of the medical instruments supplier’s stock, valued at approximately $688,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Kingswood Wealth Advisors LLC purchased a new stake in Becton, Dickinson and Company in the first quarter worth about $229,000. Brookstone Capital Management boosted its stake in shares of Becton, Dickinson and Company by 1.2% during the first quarter. Brookstone Capital Management now owns 11,725 shares of the medical instruments supplier’s stock valued at $2,901,000 after purchasing an additional 139 shares in the last quarter. Fifth Third Wealth Advisors LLC purchased a new position in Becton, Dickinson and Company during the first quarter valued at approximately $542,000. Indiana Trust & Investment Management CO increased its holdings in Becton, Dickinson and Company by 126.9% during the first quarter. Indiana Trust & Investment Management CO now owns 236 shares of the medical instruments supplier’s stock valued at $58,000 after buying an additional 132 shares during the period. Finally, Capital Asset Advisory Services LLC raised its stake in Becton, Dickinson and Company by 45.2% in the first quarter. Capital Asset Advisory Services LLC now owns 1,484 shares of the medical instruments supplier’s stock worth $365,000 after buying an additional 462 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Stock Down 0.8 %

NYSE:BDX opened at $238.62 on Friday. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $262.23. The company has a market cap of $68.96 billion, a PE ratio of 52.56, a P/E/G ratio of 1.79 and a beta of 0.42. The company’s 50 day moving average is $237.33 and its two-hundred day moving average is $235.16.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. During the same period in the previous year, the company earned $2.96 earnings per share. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. Analysts anticipate that Becton, Dickinson and Company will post 13.11 EPS for the current year.

Analysts Set New Price Targets

BDX has been the topic of a number of analyst reports. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Evercore ISI lifted their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price target for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. Raymond James reduced their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Finally, Stifel Nicolaus increased their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.